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Key messages
What is already known about this subject?
 ► Secukinumab, a fully human monoclonal igg1κ an-
tibody that selectively neutralises il-17a, provided 
sustained improvements in the signs and symptoms 
of active psoriatic arthritis (Psa) in phase iii FUtUre 
1 study over 2 years.
What does this study add?
 ► Secukinumab 150 mg (approved dose) sustained or 
further improved the clinical responses in patients 
with active Psa over 3 years in FUtUre 1 study, with 
a low rate of radiographic disease progression and 
safety profile consistent with previous reports.
How might this impact on clinical practice?
 ► this long-term (3-year) data for secukinumab in Psa 
adds to the growing body of evidence supporting the 
use of il-17 inhibitors in Psa, as recognised in the 
guidelines of european league against rheumatism 
and  group for research and assessment of Psoriasis 
and Psoriatic arthritis recommendations.
AbstrAct
Objective to assess the long-term (3 year) efficacy and 
safety of secukinumab in patients with active psoriatic 
arthritis (Psa) in the extension phase of the FUtUre 1 
study (nct01892436).
Methods Following the 2-year core trial, eligible patients 
receiving subcutaneous secukinumab 150 or 75 mg 
entered a 3-year extension phase. results are presented 
for key efficacy and safety endpoints at week 156.
Results in total, 460 patients entered the extension 
study; 308 patients originally randomised to secukinumab 
were assessed for efficacy. Sustained improvements in 
all efficacy endpoints were achieved with secukinumab 
through week 156. Overall, 76.8%/54.9% (secukinumab 
150 mg) and 65.2%/39.0% (secukinumab 75 mg) of 
patients achieved an american college of rheumatology 
(acr) 20/50 response (multiple imputation data); acr20 
responses were sustained irrespective of previous anti-
tumour necrosis factor exposure. improvements in quality 
of life and physical function were also sustained through 
week 156. radiographic results (observed data; van der 
Heijde modified total Sharp score (mtSS)) showed that 
78.1% (secukinumab 150 mg) and 74.8% (secukinumab 
75 mg) of patients had no radiographic progression (≤0.5 
increase in mtSS) through week 156. exposure-adjusted 
incidence rates for selected adverse events per 100 
patient-years (secukinumab 150/75 mg) were serious 
infections (1.7/1.6), Candida infections (1.4/0.7), crohn’s 
disease (0/0.3), ulcerative colitis (0/0.3) and major adverse 
cardiac events (0.3/0.8).
Conclusion Subcutaneous secukinumab provided 
sustained improvements in the signs and symptoms, 
quality of life and physical function of patients with active 
Psa with low rate of radiographic disease progression 
through 3 years. Secukinumab was well tolerated with no 
new safety signals.
InTROduCTIOn
Psoriatic arthritis (PsA) is a chronic, inflam-
matory disease characterised by peripheral 
arthritis, axial disease, dactylitis, enthesitis, 
and skin and nail psoriasis.1 It can be asso-
ciated with more serious comorbidities 
such as cardiovascular disease, metabolic 
syndrome and diabetes,2–4 and has a substan-
tial impact on quality of life, physical func-
tion and work productivity.5 Management of 
PsA should ideally aim to minimise articular 
pain, enthesitis, structural damage, disability 
and dermatological symptoms.1 6–8 The intro-
duction of  anti-tumour necrosis factor-α 
inhibitors (anti-TNF agents) has significantly 
improved outcomes among patients with 
PsA,6 9–11 but a proportion of patients have an 
inadequate response or poor tolerability to 
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these agents.3 12 Secukinumab, a fully human monoclonal 
antibody that selectively neutralises interleukin IL-17A,13 
has been shown to have significant efficacy in the treat-
ment of ankylosing spondylitis,13 14 moderate to severe 
psoriasis15 and PsA,16–18 demonstrating a rapid onset of 
action and sustained responses with an acceptable safety 
profile across the three indications.19 20 
In the randomised, placebo-controlled, phase III 
FUTURE 1 core study, secukinumab demonstrated rapid, 
significant and sustained reductions in the signs and 
symptoms of PsA, and inhibited radiographic progres-
sion through 2 years of treatment.16 21 The ongoing 
FUTURE 1 extension trial is a 3-year extension of the 
2-year core trial, assessing the effect of secukinumab 
on the signs and symptoms, structural damage, physical 
function and quality of life of patients with active PsA, in 
addition to evaluating long-term safety. Here, we present 
efficacy and safety results of all doses (secukinumab 150 
mg (approved dose) and 75 mg) assessed in the FUTURE 
1 study through 3 years (2 years of the core study plus 1 
year of the extension).
MeTHOds
study population
Detailed patient eligibility criteria have been reported 
previously.16 Briefly, patients were ≥18 years, with active 
PsA according to the Classification Criteria for Psori-
atic Arthritis,22 with moderate to severe symptoms for 
≥6 months, ≥3 tender joints of 78 and ≥3 swollen joints 
of 76, despite previous treatment with nonsteroidal 
anti-inflammatory drugs, disease-modifying anti-rheu-
matic drugs or anti-TNF agents. Concomitant use of 
oral glucocorticoids (up to 10 mg/day of prednisone or 
equivalent) and methotrexate (up to 25 mg/week) was 
permitted. Patients were excluded if they had previous 
therapy with biologic agents other than anti-TNF agents, 
treatment with more than three anti-TNF agents, active 
inflammatory disease other than PsA or active/history of 
ongoing infection. The study was approved by the insti-
tutional review board or ethics committee at each partic-
ipating site (Swedish Medical Centre and University of 
Washington (1143210), Dallas VAMC and University 
of Texas Southwestern Medical Centre (#IRB 14-025), 
Barts Health NHS Trust (13/WM/0365), University of 
Erlangen-Nuremberg (AZ: EK-13/081), Monash Univer-
sity (2013-08-423), University of Hasselt and Maastricht 
University Hospital (2013/1062); online supplementary 
table 1) and was conducted according to the Declaration 
of Helsinki.23
study oversight and design
The randomised, double-blind FUTURE 1 study 
(NCT01892436) was conducted across 104 sites in North 
and South America, Europe, the Middle East, Australia and 
Asia, the design of which has been previously reported.16 
Briefly, eligible patients were initially randomised to 
receive secukinumab 10 mg/kg intravenous (IV) loading 
dose at baseline and weeks 2 and 4, followed by subcuta-
neous (SC) secukinumab 150 mg or 75 mg every 4 weeks 
from week 8. Placebo was given using the same IV-to-SC 
dosing schedule. At week 16, placebo-treated patients 
were re-randomised to receive SC secukinumab 150 mg 
or 75 mg from either week 16 for placebo non-responders 
(<20% improvement from baseline in both tender 
and swollen joints) or week 24 for placebo responders. 
Randomisation was stratified by previous anti-TNF status, 
with patients being anti-TNF-naïve or anti-TNF-experi-
enced (incomplete responders who had active disease 
despite having received an anti-TNF agent for ≥3 months, 
or who had stopped treatment due to safety and tolera-
bility reasons). At the end of the 2-year core trial, eligible 
patients entered the 3-year extension phase. From week 
156, patients not adequately responding to secukinumab 
75 mg could be up-titrated to secukinumab 150 mg, at 
the discretion of investigators. See online supplementary 
figure 1 for the extension study design.
endpoints and assessments
Efficacy results at week 156 are reported for patients 
who were originally randomised to 10 mg/kg IV loading 
followed by SC 150 mg and 75 mg maintenance with 
secukinumab. The primary efficacy endpoints of this 
extension study were the proportion of patients treated 
with secukinumab 150 mg and 75 mg achieving an 
American College of Rheumatology (ACR) 20/50/70 
response over time.24 Week 156 assessments also included 
the proportion of patients achieving Psoriatic Area 
and Severity Index (PASI) 75 responses, resolution of 
dactylitis and enthesitis and proportion of patients with 
minimal disease activity (MDA). Changes from baseline 
in Disease Activity Score in 28 joints using C reactive 
protein (DAS28-CRP), Health Assessment Question-
naire–Disability Index (HAQ-DI), Medical Outcome 
Short Form (36) Health Survey (SF-36) Physical Compo-
nent Summary (PCS) and Mental Component Summary 
(MCS), and radiographic progression (measured by the 
van der Heijde modified total Sharp score (mTSS), which 
is the sum of erosion and joint space narrowing (JSN) 
scores).25 X-rays of the hands, wrists and feet, performed 
at baseline and week 156, were read centrally by two 
independent readers blinded to the treatment arms. 
The mean score was used for all analyses. Radiographic 
non-progressors were defined as patients with a change 
from baseline of ≤0.5 in mTSS during the considered 
period, as per guideline recommendations.26 Long-term 
safety and tolerability was assessed over the treatment 
period by monitoring the frequency of treatment-emer-
gent adverse events (AEs), serious AEs, laboratory abnor-
malities and vital signs.
statistical analyses
Sample size calculation estimated that 600 patients 
(200 in each secukinumab group and 200 in the 
placebo group) were sufficient to meet primary and 
key secondary endpoints. Analysis of primary and other 
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Figure 1 Patient disposition up to week 156. FAS, full analysis set; n, number of patients; SC, subcutaneous.
efficacy endpoints of the core trial have been reported 
previously.16 It was estimated that 460–520 patients would 
be eligible for enrolment in this extension study.
Evaluations of efficacy were performed on patients 
enrolled in the extension with at least one efficacy 
assessment during the extension and who were origi-
nally randomised to 10 mg/kg IV loading at baseline 
and weeks 2 and 4, followed by SC 150 mg and 75 mg 
maintenance with secukinumab starting at week 8. Effi-
cacy data from patients who discontinued the study were 
considered as end of treatment period results. No formal 
hypotheses were planned in this extension study. In the 
current analysis, missing binary variables up to week 156 
were imputed using multiple imputation. Summaries of 
continuous variables are as observed and presented as 
mean±SD. Dactylitis and enthesitis were evaluated using 
multiple imputation in the subgroup of patients with 
these symptoms at baseline. PASI response was evaluated 
in the subgroup of patients with at least 3% of the body 
surface area affected by psoriatic skin involvement.
Joint structural damage (changes from baseline in 
mTSS scores, erosion scores and JSN scores) and propor-
tion of radiographic non-progressors were analysed using 
observed data based on all evaluable patients with data at 
both baseline and week 156.
Predefined subgroup analyses were carried out on the 
basis of previous anti-TNF therapy (anti-TNF-naïve or 
anti-TNF-experienced) for key efficacy endpoints.
Safety analysis included all patients (core and exten-
sion study phase) who received ≥1 dose of secukinumab, 
with patients analysed for safety according to the actual 
treatment they received. As safety was collected over the 
treatment period and included data past week 156, safety 
analyses included patients who up-titrated from 75 mg 
to 150 mg; therefore, patients who were up-titrated were 
counted in either secukinumab group depending on the 
timing of the event. Data for selected AEs are presented 
as ted incidence rates (EAIRs) exposure-adjusted inci-
dence rate (EAIR) per 100 patient-years.
ResulTs
Patients
Of the 606 patients originally randomised in the FUTURE 
1 core trial, 460 (75.9%) patients entered the extension 
study (secukinumab 150 mg (N=162), secukinumab 75 
mg (N=148), placebo then secukinumab (N=150)). 
Figure 1 shows a breakdown of patients who entered 
the extension study. Three patients who were originally 
randomised to secukinumab and who discontinued the 
study were not part of the efficacy analyses due to the lack 
of efficacy assessment during the extension study; reasons 
for discontinuation were sudden cardiac death (150 mg 
arm), patient decision (75 mg arm) and development of 
squamous cell carcinoma of the pharynx (75 mg arm).
Within the full analysis set (FAS) population, the 
reasons for discontinuation included patient decision 
(n=7), AEs (n=5), lack of efficacy (n=5), physician deci-
sion (n=2), pregnancy (n=2) and loss to follow-up (n=1). 
The patient demographics and baseline disease char-
acteristics of patients entering the long-term extension 
phase were similar across the 150 mg and 75 mg arms 
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Table 1  Demographics and baseline characteristics of 











Age (years) 49.5±11.7 48.9±11.8
Female, n (%) 83 (51.6) 81 (55.1)
Weight (kg) 83.34±19.43 83.43±19.50
Time (years) since first 
diagnosis of PsA 8.19±8.33 7.66±8.31
Disease history and baseline characteristics
Anti-TNF-naïve, n (%) 120 (74.5) 110 (74.8)
Methotrexate use, n (%) 98 (60.9) 91 (61.9)
Systemic glucocorticoid use, 
n (%) 28 (17.4) 22 (15.0)
TJC (78 joints) 24.1±16.95 21.6±15.63
SJC (76 joints) 12.7±9.81 11.8±9.91
Psoriasis (≥3% body surface 
area), n (%) 89 (55.3) 82 (55.8)
Presence of dactylitis, n (%) 83 (51.6) 77 (52.4)
Presence of enthesitis, n (%) 99 (61.5) 91 (61.9)
*Results are mean±SD unless otherwise stated.
IV, intravenous; N, number of randomised patients; n, number 
of patients; PsA, psoriatic arthritis; SC, subcutaneous; SJC, 
swollen joint count; TJC, tender joint count; TNF, tumour 
necrosis factor.
(table 1). For secukinumab 150 mg and 75 mg, more 
than half the patients (55.3% and 55.8%) had psoriasis 
affecting at least 3% of their body surface area; 51.6% 
and 52.4% had dactylitis and 61.5% and 61.9% had 
enthesitis, respectively. A total of 25.5% and 25.2% were 
anti-TNF-experienced; 18.6% and 16.3% had received 
one anti-TNF therapy and 6.8% and 8.8% had received 
two or more anti-TNF therapies in the secukinumab 150 
mg and 75 mg arms, respectively. A total of 60.9% and 
61.9% were receiving concomitant methotrexate in the 
secukinumab 150 mg and 75 mg arms, respectively.
efficacy
Out of 460 (75.9%) patients who entered the extension 
trial, 435 (95.2%) completed 156 weeks (ie, 52 weeks of 
the extension). Sustained improvements in efficacy were 
observed during this extension study, with 76.8% and 
65.2% of patients treated with secukinumab 150 mg and 
75 mg achieving an ACR20 response and 54.9/32.9% 
and 39.0/26.0% achieving ACR50/70 responses through 
week 156, respectively (figure 2A and table 2). ACR20 
response rates were sustained through week 156, irrespec-
tive of previous anti-TNF agent exposure, with ACR20 
responses achieved by 81.0% and 67.3% of anti-TNF-
naïve patients and 61.5% and 55.6% of anti-TNF-experi-
enced patients treated with secukinumab 150 mg and 75 
mg, respectively (figure 2B). Resolution of dactylitis and 
enthesitis were sustained through week 156, with 88.1% 
and 86.8% of patients achieving dactylitis resolution and 
76.7% and 74.8% achieving enthesitis resolution in the 
150 mg and 75 mg arms, respectively (table 2 and online 
supplementary figure 2). Secukinumab also demon-
strated sustained improvement in PASI 75 responses and 
DAS28-CRP through week 156 (table 2). Proportion of 
patients with MDA response at week 156 was 43% and 
33% in secukinumab 150 mg and 75 mg, respectively 
(table 2). Improvements in physical and mental compo-
nent of quality of life (SF-36 PCS and SF-36 MCS) and 
in physical function (HAQ-DI) were sustained over the 
treatment period for secukinumab 150 mg and 75 mg 
(table 2).
Results from patients with evaluable X-ray assessments 
demonstrated that 78.1% (100/128) and 74.8% (92/123) 
of patients had no radiographic progression (mTSS score 
≤0.5) from baseline to week 156, in the 150 mg and in 
the 75 mg arms, respectively (table 3A). Mean changes in 
mTSS score from baseline to week 156 for patients in the 
150 mg and 75 mg arms are shown in table 3B. Subgroup 
analysis by anti-TNF status demonstrated that in patients 
with evaluable X-ray assessments, 78/100 (78.0%) and 
73/94 (77.7%) of anti-TNF-naïve patients and 22/28 
(78.6%) and 19/29 (65.5%) of anti- TNF-experienced 
patients were radiographic non-progressors in the 150 
mg and 75 mg groups, respectively (table 3A). Changes 
in mTSS score from baseline to week 156 in anti-TNF-
naïve patients remained low (table 3B).
safety
The incidence of AEs and serious AEs are presented in 
table 4. The EAIR per 100 patient-years of AEs in the 
any secukinumab 150 mg and 75 mg arms was 158.8 and 
128.9; the rate of serious AEs was 9.3 and 6.4, respectively. 
The most commonly reported AEs with secukinumab 
were infections and infestations, musculoskeletal and 
connective tissue disorders and gastrointestinal disor-
ders, which were stable over the long-term period of 
this study. EAIRs for serious infections and infestations, 
Crohn’s disease, ulcerative colitis, major adverse cardi-
ovascular events (MACE), inflammatory bowel disease 
and neoplasms (benign, malignant or unspecified) for 
secukinumab 150 mg and 75 mg were consistent with 
previous trials and are reported in table 4. Candida infec-
tions were reported in 12 (EAIR=1.4) and 5 (EAIR=0.7) 
patients in the any secukinumab 150 mg and 75 mg arms, 
respectively. All cases of Candida infection were mild to 
moderate in severity and resolved spontaneously with 
standard treatment or with non-drug therapy; no cases 
led to discontinuation of secukinumab treatment. One 
case of reactivation of latent tuberculosis was reported in 
the any secukinumab 150 mg arm.
Deaths (spontaneous acute myocardial infarction (n=1) 
and cardiac failure (n=1)) were reported in two patients 
with concomitant disease in the any secukinumab 150 
mg arm. Deaths occurred in three patients in the any 
secukinumab 75 mg arm including two patients (stroke 
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Figure 2 (A) ACR20/ACR50 response rates through week 156 in all patients originally randomised to secukinumab. (B) 
ACR20 response rates through week 156 in anti-TNF-nave and anti-TNF-experienced patients. Multiple imputation applied 
to missing variables through week 156. ACR, American College of Rheumatology; IV, intravenous; n, number of patients; SC, 
subcutaneous; TNF, tumour necrosis factor.
(n=1) and myocardial infarction (n=1)) with concomi-
tant disease and in one patient who developed squamous 
cell carcinoma during the study and discontinued secuki-
numab treatment on receiving the diagnosis.
dIsCussIOn
Results from the first year of the phase III FUTURE 1 
extension study have furthered our understanding of the 
role of secukinumab in the long-term treatment of PsA. 
Secukinumab demonstrated sustained improvements 
in the signs and symptoms, function and health-related 
quality of life in patients with active PsA, in addition to 
low rate of radiographic disease progression through 3 
years of treatment. Patient retention rates throughout 
this trial were high with 95.2% of the FAS population 
completing the 156-week treatment period, supporting 
the sustained efficacy and tolerability of secukinumab.
These are the first 3-year findings reported for secuk-
inumab in PsA and the data add to the growing body 
of evidence supporting the use of IL-17 inhibitors in 
PsA, as recognised in the guidelines from the European 
League against Rheumatism and Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis manage-
ment recommendations.7 27 
Consistent with previous reports, clinical benefits with 
secukinumab were observed regardless of prior exposure 
to anti-TNF therapy,28 with better responses observed in 
anti-TNF-naïve patients supporting it use as a treatment 
for patients with PsA naïve to anti-TNF therapy and those 
who have experienced an inadequate response or intol-
erance to these agents.6 29–32
The IL-17 pathway plays a role in irreversible structural 
damage experienced during inflammatory arthritis,33–36 
as indicated by the increased presence of IL-17+CD8+ 
T-cells in the joints of patients with PsA.33 Previously 
published results from the FUTURE 1 study have demon-
strated that secukinumab significantly inhibited radio-
graphic progression in patients with PsA versus placebo at 
week 24,37 with sustained inhibition through 2 years.16 28 
Results reported here extend these findings up to 3 years 
of treatment.
The safety profile of secukinumab in this trial was 
consistent with previous reports in patients with PsA 
and moderate-to-severe plaque psoriasis, with no new 
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Table 2  Secondary efficacy endpoints at weeks 52, 104 



























































*Multiple imputation applied to missing variables through week 
156.
†Analysis performed in randomised patients with psoriasis 
affecting ≥3% body surface area (psoriasis subset).
‡Observed data through week 156.
§Resolution of dactylitis and enthesitis are shown for patients 
with these symptoms at baseline (dactylitis: N=83 (150 mg) and 
77 (75 mg); enthesitis: N=99 (150 mg) and 91 (75 mg). Results 
are mean±SD unless otherwise stated.
ACR, American College of Rheumatology; DAS28-CRP, 
Disease Activity Score in 28 joints using C-reactive protein; 
HAQ-DI, Health Assessment Questionnaire–Disability Index; IV, 
intravenous; MCS, mental component summary; MDA, minimal 
disease activity; N, number of randomised patients; PASI, 
Psoriasis Area and Severity Index; PCS, physical component 
summary; SC, subcutaneous; SF-36, medical outcomes study 
36-item Short Form-36 Health Survey.
Table 3A Proportion of radiographic non-progressors
Secukinumab








progressors, n/M (%) 100/128 (78.1) 92/123 (74.8)
Anti-TNF-naïve 
patients 78/100 (78.0) 73/94 (77.7)
Anti-TNF-experienced 
patients 22/28 (78.6) 19/29 (65.5)
IV, intravenous; M, number of patients who have a non-
missing response status in the treatment group; n, number of 
patients who are non-progression responders (non-progression 
responders were patients with a change from baseline of 
≤0.5 in van der Heijde modified Total Sharp Score during the 
considered period); SC, subcutaneous; TNF, tumour necrosis 
factor.
or unexpected safety signals observed.15–17 The most 
common AEs observed (infections and infestations, 
musculoskeletal and connective tissue disorders, and 
gastrointestinal disorders) and serious AEs are consistent 
with data from previous reports in patients receiving 
secukinumab and placebo.16
Patients with PsA have been reported to have a possible 
elevated risk of cardiovascular disease38–40 when treated 
with anti-IL-12/23 agents,41 42 and thus cardiovascular AEs 
are of interest in patients treated with biological agents. 
In our study, the EAIRs of MACE were 0.3 and 0.8 in the 
any secukinumab 150 mg and 75 mg groups, respectively. 
This is in line with previously reported rates of MACE 
in secukinumab-treated patients, including those from 
the FUTURE 1 core study,15 16 28 and corroborate results 
from a recent meta-analysis showing a low overall MACE 
rate in patients with psoriasis who were treated with 
the IL-17A inhibitors, secukinumab and ixekizumab.43 
Candida infections observed during this study are consis-
tent with results from phase III studies, including the 
FUTURE 1 core study, in patients with PsA17 28 and psori-
asis.15 All cases were mild to moderate in severity, did not 
lead to discontinuation and were managed with standard 
antifungal therapy. Increased rate of Candida infections 
is likely attributable to the role of IL-17 in host defense 
against fungal infections, particularly at mucosal sites.44 
Other AEs of special interest in this study, including 
Crohn’s disease and ulcerative colitis, were low and in line 
with previously reported findings, including those from 
the FUTURE 1 core study.16 20 They also confirm results 
from a recent review of phase II and III studies where 
patients with PsA treated with secukinumab (up to 112 
weeks) had EAIRs of 0.07 for Crohn’s disease and 0.14 for 
ulcerative colitis.45 No suicides or suicide ideation were 
reported during this study.
While this study was not specifically designed to 
examine the psychological impact of secukinumab treat-
ment on patients with PsA, an improvement in emotional 
role functioning and mental health was observed with 
secukinumab treatment, as assessed by the patient-re-
ported SF-36 MCS.46
Limitations of this study included a lack of a long-term 
comparator due to the fact that long-term treatment with 
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Table 3B  Mean change in X-ray assessments from 
baseline to week 156 (mTSS score, erosion score and JSN 












No of patients 
evaluated
128 123
  mTSS score Baseline 16.9±34.52 16.3±32.30
Change† 1.9±8.49 2.0±6.44
  Erosion score Baseline 8.1±16.88 7.7±14.63
Change† 1.1±5.31 1.0±3.57





No of patients 
evaluated
100 94
















No of patients 
evaluated
28 29












Values are as mean±SD.
*Observed data.
†Change from baseline to week 156. Only patients with a value 
at each time point are presented.
IV, intravenous; JSN, joint space narrowing; mTSS, van der 
Heijde modified total Sharp score; N, total number of patients 
in specified group; SC, subcutaneous; TNF, tumour necrosis 
factor.











Exposure to study treatment 
(days), mean±SD
754.0±509.4 940.1±340.3
Death, n (%) 2 (0.5) 3 (1.0)
Discontinuation due to AEs, 
n (%)
20 (4.6) 20 (6.8)
Any AEs, n (EAIR) 321 (158.8) 248 (128.9)
Any serious AEs, n (EAIR) 73 (9.3) 45 (6.4)
AEs of special interest, n (EAIR)
  Serious infections and 
infestations
15 (1.7) 12 (1.6)
  Candida infections 12 (1.4) 5 (0.7)
  Crohn's disease 0 (0) 2 (0.3)
  Ulcerative colitis 0 (0) 1 (0.1)
  MACE 3 (0.3) 6 (0.8)
*Includes all patients who were administered with at least one 
dose of study treatment during the core or the extension study. 
Patients who were up-titrated (N=139) were counted in either 
secukinumab groups depending on the timing of the event. If a 
patient experienced an AE after up-titration, the corresponding 
AE was counted at the up-titrated dose.
AE data presented as n (EAIR per 100 patient-years) unless 
otherwise stated.
AE, adverse event; EAIR, exposure-adjusted incidence rate; 
IV, intravenous; MACE, major adverse cardiac events; SC, 
subcutaneous.
placebo is considered unethical; the placebo-controlled 
period of the core trial was, therefore, only up to week 
16. There was no active comparator included and results 
could be potentially biased as patients remaining in the 
study are those patients benefiting from secukinumab. 
While efficacy responses in the current study were 
sustained irrespective of previous anti-TNF exposure, 
patients eligible for inclusion in this study could have 
been treated with no more than three anti-TNF agents; 
this may be viewed as a limitation of the study.
In summary, secukinumab provided sustained improve-
ments across multiple domains of PsA including signs and 
symptoms, quality of life and physical function in patients 
with active disease, in addition to low rate of radiographic 
disease progression through 3 years of treatment. The 
results confirmed a favourable and consistent safety 
profile through 3 years, which is comparable with that 
reported through 2 years in the core trial. Overall, the 
results of this extension study provide further supporting 
evidence for the long-term use of secukinumab in the 
treatment of patients with PsA.
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